# STALICLA

> STALICLA is a Swiss clinical-stage biopharmaceutical company pioneering precision medicine for neurodevelopmental disorders (NDD), including autism spectrum disorder (ASD). It uses a clinically validated neuro-precision development platform to stratify patient subgroups and develop tailored treatments.

## Company

- [About](https://stalicla.com/about): Company mission, leadership, and team.
- [Contact](https://stalicla.com/contact): Contact details and inquiries.

## Technology

- [DEPI Platform](https://stalicla.com/our-technology/depi-platform): STALICLA's precision-medicine drug development platform.
- [For Industry Partners](https://stalicla.com/our-technology/for-industry-partners): Partnership and collaboration opportunities.

## Pipeline

- [Pipeline](https://stalicla.com/pipeline): Clinical-stage drug development pipeline, including STP1 and STP7 (Mavoglurant).

## For Patients

- [Neurodevelopmental Disorders (NDD)](https://stalicla.com/for-patients/ndd): Information for patients with neurodevelopmental disorders.
- [Substance Use Disorders (SUD)](https://stalicla.com/for-patients/sud): Information for patients with substance use disorders.

## Media

- [Media](https://stalicla.com/media): Press and media overview.
- [News](https://stalicla.com/media/news): Company news and press releases.
- [Events](https://stalicla.com/media/events): Conference appearances and events.
- [Publications](https://stalicla.com/media/publications): Scientific publications.

## Legal

- [Privacy Policy](https://stalicla.com/clauses/privacy-policy)
- [Terms and Conditions](https://stalicla.com/clauses/terms-and-conditions)
- [Disclaimer](https://stalicla.com/clauses/disclaimer)